SBIR Phase II: Design and production of a next generation vaccine to prevent COVID — NSF Award to OMNICYTE, LLC (CT, $997,689)
The broader impact of this Small Business Innovation Research (SBIR) Phase II project is to develop a next-generation communicable disease vaccine that addresses weaknesses of current vaccines such as ineffective boosters. The proposed project aims to produce a next-generation vaccine that has better efficacy and signi
| Award title | SBIR Phase II: Design and production of a next generation vaccine to prevent COVID |
|---|---|
| Award ID | 2313338 |
| Awardee | OMNICYTE, LLC |
| City | GUILFORD |
| State | CT |
| Amount obligated | $997,689 |
| Principal investigator | Peter Leonardi |
| Program | SBIR Phase II |
| Start date | 03/15/2024 |
| Abstract | The broader impact of this Small Business Innovation Research (SBIR) Phase II project is to develop a next-generation communicable disease vaccine that addresses weaknesses of current vaccines such as ineffective boosters. The proposed project aims to produce a next-generation vaccine that has better efficacy and significantly reduced side effects, as well as increased duration of effectiveness. The proposed project intends to produce a next-generation vaccine that can aid in vaccinating to prev |
| Source | NSF Awards |
$799/mo
Try NSFGrants →